InvestorsHub Logo
Followers 2
Posts 298
Boards Moderated 0
Alias Born 08/16/2010

Re: None

Wednesday, 10/13/2010 6:19:05 AM

Wednesday, October 13, 2010 6:19:05 AM

Post# of 6
PAION COMPLETES PHASE IIB STUDY WITH SHORT-ACTING
ANESTHETIC/SEDATIVE REMIMAZOLAM (CNS 7056)

· Phase IIb study completed within 4 months
· Headline data expected by end of November
· No safety concerns

http://www.paion.de/images/stories/investoren/finanznachrichten/2010/en/paionp100927en.pdf